Talk:RET proto-oncogene

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Molecular and Cell Biology task force (assessed as Low-importance).

Formerly MEN2a/2b

MEN2a and 2b are the CURRENT names, MEN 3 is outdated following the discovery that MEN2B was caused by a mutation to the same gene (met->thr mutation on RET). I've changed the article accordingly. —Preceding unsigned comment added by ChillyMD (talk • contribs) 13:53, 23 January 2009 (UTC)[reply]

As a drug target

Cabozantinib Improves Outcomes Over Erlotinib in Advanced NSCLC says cabozantinib is also an inhibitor of RET and ROS1. May explain good results in NSCLC. - Rod57 (talk) 11:59, 3 December 2016 (UTC)[reply]

Talk:RET proto-oncogene

Formerly MEN2a/2b

As a drug target

Navigation menu

Search